ANTX vs OMER
ANTX: AN2 Therapeutics leverages a proprietary boron chemistry platform to develop small-molecule drugs for neglected infectious diseases, blood cancers, and other high-unmet-need conditions. OMER: A clinical-stage biotech company commercializing complement-pathway inhibitors for rare hematologic and immune diseases, with FDA-approved YARTEMLA for stem cell transplant complications and a $240M asset sale of its lead MASP-3 program to Novo Nordisk.
Side-by-side fundamentals
| Metric | ANTX | OMER | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $4.89 | $9.84 | |
| Market cap as of 2026-07-23 | $176M | $703M | |
| P/E as of 2026-07-23 | n/a | 8.16 | |
| Net margin as of 2026-07-23 | n/a | +566.7% | |
| Gross margin as of 2026-07-23 | n/a | +94.1% | |
| Operating margin as of 2026-07-23 | n/a | -176.1% | |
| ROE as of 2026-07-23 | -52.3% | +107.5% | OMER higher |
| ROA as of 2026-07-23 | -47.3% | +34.5% | OMER higher |
| Debt / equity as of 2026-07-23 | 0.00 | 21.55 | ANTX lower |
| Revenue CAGR (3y) SEC XBRL | n/a | +4.4% | |
| Beta as of 2026-07-23 | -1.00 | 2.59 | |
| 1-year return as of 2026-07-22 close | +342.5% | +163.1% | ANTX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.